Kosei Taniguchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kosei Taniguchi has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Kazutoshi Fujita
Department of Urology Kindai University Faculty of Medicine Osaka Japan
1 shared publication - Mamoru Hashimoto
Department of Urology Kindai University Faculty of Medicine Osaka Japan
1 shared publication Marco Antonio De Velasco
Department of Urology Kindai University Faculty of Medicine Osaka Japan
1 shared publicationOsamu Maenishi
Department of Pathology Kindai University Faculty of Medicine Osaka Japan
1 shared publicationSaizo Fujimoto
Department of Urology Kindai University Faculty of Medicine Osaka Japan
1 shared publicationShingo Toyoda
Department of Urology Kindai University Faculty of Medicine Osaka Japan
1 shared publication
Latest Publications
- Open Access
- 19 February 2026
- Published by Wiley in IJU Case Reports
- Vol. 9 (2)
A Case of Upper Tract Urothelial Carcinoma With Neuroendocrine Differentiation Successfully Treated With Enfortumab Vedotin and Pembrolizumab
Introduction: Upper tract urothelial carcinoma with neuroendocrine differentiation (UC‐NE) is extremely rare and generally associated with aggressive behavior and poor prognosis. Optimal treatment strategies remain unclear, particularly regarding the role of nectin‐4–targeted therapy. Case Presentation: A 61‐year‐old man was diagnosed with UC‐NE of the renal pelvis. Laparoscopic nephroureterectomy revealed invasive UC‐NE with lymphatic invasion (pT1, G2) and carcinoma in situ of the ureter (pTis, G1). Immunohistochemistry showed strong nectin‐4 expression in the urothelial component but only weak to moderate expression in the neuroendocrine component. Ten months after surgery, para‐aortic and bilateral pelvic lymph node recurrence developed. Treatment with enfortumab vedotin (EV) plus pembrolizumab achieved a complete response after 3 cycles, and remission was maintained with continued therapy. Conclusion: This case suggests that EV plus pembrolizumab may be effective for UC‐NE and highlights the importance of evaluating nectin‐4 and the tumor immune microenvironment when considering treatment strategies for this rare subtype.
- 19 February 2026
- Published by Wiley in IJU Case Reports
- Vol. 9 (2)
Open AccessA Case of Upper Tract Urothelial Carcinoma With Neuroendocrine Differentiation Successfully Treated With Enfortumab Vedotin and Pembrolizumab
Introduction: Upper tract urothelial carcinoma with neuroendocrine differentiation (UC‐NE) is extremely rare and generally associated with aggressive behavior and poor prognosis. Optimal treatment strategies remain unclear, particularly regarding the role of nectin‐4–targeted therapy. Case Presentation: A 61‐year‐old man was diagnosed with UC‐NE of the renal pelvis. Laparoscopic nephroureterectomy revealed invasive UC‐NE with lymphatic invasion (pT1, G2) and carcinoma in situ of the ureter (pTis, G1). Immunohistochemistry showed strong nectin‐4 expression in the urothelial component but only weak to moderate expression in the neuroendocrine component. Ten months after surgery, para‐aortic and bilateral pelvic lymph node recurrence developed. Treatment with enfortumab vedotin (EV) plus pembrolizumab achieved a complete response after 3 cycles, and remission was maintained with continued therapy. Conclusion: This case suggests that EV plus pembrolizumab may be effective for UC‐NE and highlights the importance of evaluating nectin‐4 and the tumor immune microenvironment when considering treatment strategies for this rare subtype.